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ABSTRACT 
Objective: To determine the effect of adding biomarker feedback (expired air carbon-
monoxide) to standard quit advice on cognitive antecedents of behaviour change and 
smoking cessation and to identify potential effect moderators and mediators. 
Design: Smokers (N=160) were randomised to a control (quit advice plus leaflet) or an 
intervention condition (as control group plus carbon-monoxide level feedback). Cognitive 
measures were assessed immediately after the intervention and behavioural measures 
at six months follow-up. 
Main Outcome Measures: Primary outcome measures were threat and efficacy 
appraisal, fear arousal and intention to stop smoking. Secondary outcome measures 
were quit attempts within the last six months and 7-day point prevalence abstinence. 
Results: Threat appraisal was significantly enhanced in the intervention compared with 
the control group (t(158)=2.29, p=0.023) as was intention to stop smoking in the next 
month (t(151)=2.9, p=0.004). However, this effect on intention to stop smoking was 
short-lived. Groups did not differ in terms of quit attempts or abstinence at follow-up, but 
the intervention increased the likelihood of cessation in smokers with higher self-efficacy 
(χ2(1)=5.82, p=0.016). 
Conclusions: Carbon-monoxide level feedback enhances the effect of brief quit advice 
on cognitive antecedents of behaviour change and smoking cessation rates but further 
research is required to confirm the longevity of this effect and its applicability to smokers 
with low self-efficacy. 
Key words: smoking cessation interventions, fear appeal, biomarker feedback, expired 
air carbon-monoxide, self-efficacy
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INTRODUCTION 
Tobacco use remains the leading cause of premature, preventable deaths worldwide 
killing more people than HIV, illicit drug use and alcohol combined (Ezzati & Lopez, 
2003). Smoking rates are still on the rise in many low-and middle income countries and 
prevalence reductions have stalled in most developed countries (Mackay, Eriksen, & 
Shafey, 2006). Consequently, there is an unmet need for the development of new 
smoking cessation interventions to reduce smoking prevalence and prevent future 
deaths from smoking. One approach to smoking cessation interventions is to provide 
smokers with biomarker feedback evidencing smoking-related risk or harm. Health is 
often cited as one of the main reasons for people attempting to stop smoking (Vangeli & 
West, 2008). However, simply telling people they are at risk of developing a disease in 
the future is seldom enough to change behaviour (Leventhal, Benyamini, Brownlee, 
Diefenbach, Leventhal et al., 1997). For this reason, making threatening information 
more salient, as in the case of fear appeals using biomarkers, has been proposed as a 
more effective approach (Witte & Allen, 2000). 
 
A number of models have been used to explain the likely mode of action of fear appeals; 
in particular social cognition models such as the Drive Reduction Model, Protection 
Motivation Theory or the Parallel Response Model have been ubiquitously used (Ruiter, 
Abraham, & Kok, 2001). The Extended Parallel Process Model (EPPM, Witte, 1992) 
attempts to unify and improve on earlier models, postulating that fear appeals trigger 
coping responses, such as fear control and danger control. People engage in protective 
behaviour and danger control only when they perceive themselves to be susceptible to 
severe threats (threat appraisal) and feel that they are able to perform a behaviour (i.e. 
display self-efficacy) that is effective (i.e. has response efficacy) in averting this risk 
(efficacy/coping appraisal). If no threat is perceived, there is no response to the fear 
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appeal. In contrast, when people perceive a threat and positively appraise their efficacy 
to avert this threat, they are motivated to protect themselves and thus accept the fear 
appeal message and engage in a behavioural solution (e.g. smoking cessation). 
Evidence from a meta-analysis suggests that the stronger the fear reaction, the higher 
the likelihood of a desired effect (Witte & Allen, 2000). However, threat in the absence of 
a sufficient level of self-efficacy is unlikely to increase motivation to stop smoking 
(Bishop, Marteau, Hall, Kitchener, & Hajek, 2005). Indeed, in the context of smoking, 
self-efficacy has been argued to be instrumental to the way in which fear impacts on 
subsequent behaviour (Dijkstra & Brosschot, 2003) as it could result in the opposite 
effect because low efficacy appraisal in the presence of a threat leads to an increase in 
fear levels according to the EPPM. Consequently, a person will become defensive and 
be more concerned with managing their fear rather than the causes of their fear. People 
may distort or deny the meaning of threatening information (disengagement beliefs, 
Bandura, 1986) and engage in cognitive (i.e. avoidance) rather than behavioural (i.e. 
quitting) solutions. 
 
At the neurophysiological level, it has been proposed that these cognitions are 
underpinned by fear structures in the limbic system and associated areas that process 
emotional stimuli to compute appropriate responses (Keightley, Winocur, Graham, 
Mayberg, Hevenor et al., 2003). This fear network is activated through the presentation 
of fear-inducing material and the provision of fear congruent or incongruent material is 
then thought to either strengthen or weaken the respective fear structure according to 
emotional processing (EP) theory (Foa & Kozak, 1986). The general outline of this 
theory is supported by the success of exposure therapy in treating various phobias 
(Barlow, 1988) and fear appeals in changing behaviour (Witte & Allen, 2000), both of 
which are aimed at reducing or increasing fear levels, respectively. 
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Based on the reviewed fear appeal and emotional processing literature, it is suggested 
that fear appeals function by their ability to access neurologically based cognitive fear 
networks by increasing physiological arousal through the provision of fear-inducing 
material, thereby initiating emotional processing as expressed by increased fear levels. 
Biomarkers, as one form of fear appeal, are thought to achieve this due to the nature of 
the stimulus provided; by personalising information, they counteract perceptions of 
invulnerability to the health consequences of tobacco-use, which are common among 
smokers (Strecher, Kreuter, & Kobrin, 1995), thus raising arousal levels and threat 
perceptions. Socio-cognitive models of persuasion like the elaboration likelihood model 
(Petty & Cacioppo, 1986) would predict that only messages that are considered relevant 
for oneself are thoroughly analysed and thus lead to stronger changes in attitudes, which 
would favour personalised feedback. Further, while biomarkers may provide confirmation 
of exposure and thus possible harm caused by smoking, they are also helpful in 
evidencing positive changes in the body after smoking cessation, which would increase 
a smoker’s perception of the response efficacy of cessation. Lastly, biomarkers provide 
a clear and coherent message about the inherent harm associated with exposure to 
smoking, which should reduce the likelihood of the threat message being derogated. 
 
Notwithstanding the rationale for using biomarkers, a recent Cochrane review suggests 
that there is currently insufficient evidence to make a definitive statement about the utility 
of biomedical risk assessment as an aid for smoking cessation (Bize, Burnand, Mueller, 
Rege, & Cornuz, 2009). This study aimed to add to this literature by investigating the 
impact of providing feedback of expired-air carbon-monoxide levels to smokers on 
cognitive antecedents of behaviour change. There exists a multitude of biomarkers that 
evidence exposure to smoking (e.g. cotinine), risk (genetic markers) or actual harm 
caused by smoking (e.g. atherosclerotic plaque). However, in contrast to these 
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biomarkers, determining carbon-monoxide levels is quick, relatively inexpensive and not 
invasive, making it an ideal addendum to existing interventions. Feedback of carbon-
monoxide levels on its own has had varying success in changing smokers’ behaviour but 
tends to increase smoking cessation rates when compared with minimal control 
conditions (Jamrozik, Vessey, Fowler, Wald, Parker et al., 1984; Sanders, Fowler, Mant, 
Fuller, Jones et al., 1989) and when incorporated with motivational interviewing 
increases abstinence compared with standard treatment (Borrelli, McQuaid, Novak, 
Hammond, & Becker, 2010). Moreover, carbon-monoxide levels are routinely assessed 
in UK smoking cessation services (McNeill, Raw, Whybrow, & Bailey, 2005) mainly as a 
means of validating abstinence. Providing tailored advice on what high expired air 
carbon-monoxide levels mean for toxin intake and health may offer an opportunity for 
further increasing motivation to stop smoking and due to the simplicity of this 
intervention, it may also be a useful addition to brief advice by physicians. 
 
This randomised trial therefore aimed to assess the short- and long-term efficacy of 
adding tailored carbon-monoxide feedback to brief standard quit advice. In particular, we 
tested the hypotheses that combining biomarker feedback with generic quit advice will 
lead to: 
1.) Appropriate changes in cognitive antecedents of behaviour change (increase in 
threat appraisal, self-reported fear levels and intention to stop smoking) compared with 
generic quit advice alone (primary outcomes). 
2.) Appropriate changes in behaviour (increase in quit attempts and smoking cessation 
rates) at 6 months follow up compared with generic quit advice alone (secondary 
outcomes). On the basis of EPPM and EP, it was further postulated that impact of the 
intervention on smoking cessation would be moderated by self-efficacy and mediated by 
fear levels. 
 8 
METHODOLOGY 
Procedure 
This randomised control trial was carried out in 2006/7 at University College London as 
part of a laboratory study that assessed the differential exposure of hand-rolled and 
manufactured cigarette smokers to carcinogens (see Shahab, West, & McNeill, 2009). 
Participants were recruited from the general population through advertisements in local 
newspapers, flyers, emails, or posters on public bulletin boards at and around University 
College London. The study was presented as a laboratory-based study, not as an 
intervention study, and smokers were not required to intend to stop smoking. Smokers 
who responded to the advertisements were screened for eligibility through a telephone 
interview and provided with information about the study. Participants were included if 
they were between 18 and 60 years of age and had smoked more than five cigarettes 
daily for the past year. Smokers were ineligible if they had a history of lung or heart 
disease or if they were pregnant. 
 
Participants visited the laboratory on two occasions, 24 hours apart. At the first visit, the 
main purpose of the study, as pertaining to the measurement of exposure to 
carcinogens, was explained and participants were asked to sign a consent form. At this 
stage participants also completed the baseline questionnaire (T1). Following the 
questionnaire, smokers provided a breath sample both before and after having smoked 
a cigarette by blowing into a monitor which analyses expired carbon-monoxide (CO) 
content. Since alveolar CO levels change relatively rapidly with exposure to cigarette 
smoke, participants were asked to refrain from smoking half an hour before each 
laboratory sessions to obtain a standardised reading. Urine and saliva samples were 
also collected. At the beginning of the second visit, 24 hours later, the researcher 
randomly assigned participants to the control or treatment condition by means of 
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opening a sealed envelope containing the random number generated group allocation 
(restricted to equal numbers per group). Participants were blinded to the allocation but 
this was not possible for the researcher providing the intervention. Participants again 
provided a breath sample before and after smoking a cigarette before urine and saliva 
samples were collected. Both the control and experimental group were provided with a 
generic leaflet about lung disease. The control group received standardised brief advice 
to quit smoking; the treatment group also received brief targeted feedback about their 
CO levels in relation to the development of cardiovascular and respiratory diseases. At 
the end of the session, all participants completed the outcome questionnaire (T2); 
received a debriefing letter (in the treatment group with the personalised CO reading); 
agreed to being contacted for a follow-up phone call (all participants consented) and 
received £50 for their time. Six months after the second laboratory visit, participants 
were contacted by a researcher blinded to group allocation to complete the follow-up 
questionnaire (T3). If participants did not answer their phone on more than three 
occasions, they were contacted by email and if this failed by, post. The study received 
ethical approval form the UCL Ethics Committee. 
 
Participants 
A total of 160 participants were included in this study, of whom, 51 (31.9%) were lost to 
follow-up (see Figure 1); there were no significant differences between groups in terms 
of attrition. Participants lost to follow-up did not differ on any of the assessed 
demographic or cognitive variables other than age; those lost to follow-up were younger 
than those who remained in the study (t(119)=2.2, p=0.027). The characteristics of 
included participants are presented in Table 1. 
 
Figure 1 about here 
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Intervention 
Everybody received a generic leaflet about the dangers of smoking and respiratory 
disease. In addition to the leaflet, smokers in the control group were given standardised 
brief quit advice (“I would urge you to stop smoking; quitting is the single-most important 
thing you can do to feel better & improve your health”) while smokers in the intervention 
group also received individualised brief quit advice that related their carbon-monoxide 
reading to cardiovascular, malignant and non-malignant lung diseases. A post-doctoral 
researcher described how carbon monoxide (CO) from smoking causes damage and 
illustrated how their CO reading relates to disease risk on a chart plotting smoking 
intensity against risk of developing heart and airways disease (‘Your CO reading 
suggests that you smoke cigarettes very intensely and this means you are at greater risk 
of suffering heart problems and lung cancer as shown on this graph’). Participants in this 
group were also given a print-out that included their personal CO level in order to make 
the result more salient. This intervention lasted about three minutes and was aimed to 
increase smokers’ perception of their own susceptibility to smoking-related diseases and 
thus raise fear levels regarding smoking in order to increase quit intentions and motivate 
cessation. Participants in the control group were not shown their CO reading and told 
that the measurement of expired air was standard procedure for the laboratory study. 
 
Leaflet 
A leaflet was developed and piloted on smokers attending a smoking cessation clinic in 
North London between January and February 2006. This leaflet contained information 
about the link between smoking and respiratory illnesses and was designed to increase 
smokers’ awareness of both the seriousness of these diseases and their risk of 
developing diseases thus manipulating perceived severity and susceptibility. In addition, 
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the leaflet also contained information about the effectiveness of smoking cessation for 
preventing smoking-related diseases (thus attempting to raise perceived response 
efficacy) as well as practical information about how to get support for quitting smoking 
(attempting to raise perceived self-efficacy). 
 
Measures 
Biomarkers (expired air carbon-monoxide and cotinine) 
A standard monitor (Smokerlyzer®, Bedfont Scientific Ltd, Kent, UK) was used to obtain 
expired air carbon monoxide levels. A reading was taken before and after having 
smoked a cigarette following a minimum of a half-hour interval of not smoking. Carbon-
monoxide monitors provide a valid and reliable measure of expired air CO levels (Jarvis, 
Belcher, Vesey, & Hutchison, 1986) which have been related to a number of lung 
diseases including COPD, cystic fibrosis and asthma (Kharitonov & Barnes, 2002) as 
well as lung cancer (Law, Morris, Watt, & Wald, 1997) and carbon-monoxide is one of 
the cigarette constituents believed to be involved in cardiovascular disease (Ludvig, 
Miner, & Eisenberg, 2005). 
Saliva samples were collected using a dental roll, which participants were asked to keep 
in the mouth until saturated. Samples were assayed for cotinine, a major metabolite of 
nicotine that provides a very sensitive and specific quantitative measurement of tobacco 
intake using a tandem mass spectrometric method.(Feyerabend & Russell, 1990) 
Sociodemographic Characteristics (T1) 
Participants were asked about general demographic characteristics (age, gender) in the 
baseline questionnaire. In addition, deprivation level was determined using the Index of 
Multiple Deprivation (IMD), a measure of relative poverty based on post codes (Jordan, 
Roderick, & Martin, 2004). Body mass index (BMI) was calculated from participants’ self-
reported height and weight (kg/m2). 
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Smoking Characteristics (T1) 
The baseline questionnaire T1 also asked for information on participants’ smoking 
history, quit attempts (‘Have you attempted to stop smoking at all in the last 5 years’?) as 
well as nicotine dependence using the Heaviness of Smoking Index, a short version of 
the Fagerström test for nicotine dependence (Heatherton, Kozlowski, Frecker, Rickert, & 
Robinson, 1989). 
Cognitive (primary) outcomes (T1, T2) 
Cognitive outcomes were assessed at the baseline (T1) and outcome (T2) 
questionnaire. Fear about smoking was assessed using two questions on 7-point scales 
(Dijkstra & Brosschot, 2003) with content-specific anchors regarding airway disease (‘not 
at all afraid’ and ‘very afraid’; ‘not at all worried’ and ‘extremely worried’) and the mean 
items score was used (Cronbach’s α 0.79-0.80). Perceived severity and susceptibility 
were measured with two single 7-point response scales each with content-specific 
anchors regarding airway disease, which have been successfully used in similar form 
before (Hall, Weinman, & Marteau, 2004). For perceived susceptibility, participants were 
asked to rate their likelihood as well as risk (in comparison with non-smokers) of 
developing airway disease (from ‘very unlikely’ to ‘very likely’ and ‘much higher’ to ‘much 
lower’, respectively; Cronbach’s α 0.61-0.66). For perceived severity, participants were 
asked whether they believed that airway disease was a.) a serious disease and b.) a 
severe illness (both from ‘strongly agree’ to ‘strongly disagree’; Cronbach’s α 0.82-0.84). 
Perceived response efficacy and self-efficacy were assessed by two 7-point rating 
scales each, and the respective mean item score was used. Both measures have been 
shown to display good reliability (Hall, Bishop, & Marteau, 2003). Response efficacy was 
determined by asking smokers whether they believed that stopping smoking can a.) 
reduce their risk and b.) their likelihood of getting airway diseases (both from ‘strongly 
agree’ to ‘strongly disagree’; Cronbach’s α 0.66-0.70). Self-efficacy (the belief that one 
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can do something, e.g. change a given behaviour) was assessed by asking participants 
how confident they are to be able to stop smoking (from ‘very confident’ to ‘not at all 
confident’) and how easy it would be for them to stop smoking (from ‘very easy’ to ‘not at 
all easy’; Cronbach’s α 0.70-0.78). In addition, participants were asked about their 
intention to stop smoking in the next month measured using two 7-point Likert response 
scales ranging from ‘very unlikely’ to ‘very likely’, and ‘definitely will’ to ‘definitely will not’ 
(Cronbach’s α 0.73-0.86). While intention to stop smoking does not form part of either 
the EPPM or EP, we have included it here as an immediate measure of potential 
changes in subsequent behaviour. For each of the measures, the mean value was used 
in analysis. 
Behavioural (secondary) outcomes (T3) 
At 6 months follow-up participants were asked to indicate their current smoking status 
(“Have you smoked in the last seven days?” Yes/No), whether they had attempted to 
stop smoking as well as their intention to stop smoking in the next month (see above). 
 
Analysis 
This study was powered for the laboratory study, which provided 80% power at a 
standard Type I error rate (α=0.05) to detect a medium-to-large effect size (Cohen’s 
d~0.5-0.7) for group differences in primary (cognitive) and secondary (behavioural) 
outcomes in a two-tailed comparison of means or proportions. This effect size for 
cognitive outcomes is largely comparable to those found in previous studies with similar 
measures and intervention design (Hall et al., 2003; Hall et al., 2004; Shahab, Hall, & 
Marteau, 2007). Change scores were calculated from responses to baseline and 
outcome questionnaire for cognitive outcomes. Although interactions between group and 
outcome variables could be assessed with repeated measures ANOVA, change scores 
were calculated and group differences assessed as this yields equivalent results and 
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has the advantage that non-parametric tests can be used to determine interactions. 
Group differences were tested with t-tests, changes within groups with paired t-tests and 
where appropriate Mann-Whitney U and Wilcoxon tests were used to validate results. 
Multivariate logistic regression was used to predict behavioural outcomes using 
treatment allocation, socio-demographic and smoking characteristics and where 
appropriate cognitive measures as predictors. Where it was impossible to use regression 
owing to the distribution of data, log-linear models were fitted in order to be able to 
estimate moderation effects. Mediation (using the Sobel method) and moderated 
mediation were analysed with bootstrapping in SPSS (Preacher, Rucker, & Hayes, 
2007). All analyses of behavioural outcomes used an intention-to-treat approach. 
 
RESULTS 
The study sample was relatively young with a mean age of 31 and slightly more men 
than women (Table 1). Participants had been smoking for an average of 14 years and 
smoked nearly 14 cigarettes per day. The majority had attempted to quit in the last five 
years but only a tenth agreed or very strongly agreed with the statement that they were 
intending to stop smoking in the next month. There were no differences on baseline 
demographic or smoking characteristics between the intervention and control group. 
 
Table 1 about here 
 
1.) Primary outcomes 
The level of perceived response efficacy as well as perceived susceptibility increased 
significantly from Visit 1 to Visit 2 in both the intervention and control group and self-
efficacy only in the intervention group (Table 2). While perceived severity was the only 
cognitive measure that did not increase across visits in either group, possibly due to a 
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ceiling effect as baseline levels were already very high (average of 5.7 and 5.3 on 7-
point scale in control and treatment group, respectively), as hypothesised threat 
appraisal in the form of perceived susceptibility increased significantly more in the 
intervention than control group (t(158)=2.33, p=0.021). 
 
Table 2 about here 
 
Although self-reported fear levels were significantly increased across visits in the 
intervention group only (t(80)=3.2, p=0.002), this increase was not significant relative to 
the control group (t(158)=1.4, p=0.180). As predicted, participants in the intervention 
group displayed a greater rise in their reported intention to stop smoking in the next 
month than those in the control group (t(151)= 2.9, p=0.004). Yet, this increase was 
short-lived. As shown in Figure 2, when only looking at participants with complete data 
and excluding those who had stopped at the time of follow-up (N=51 and N=48 for 
control and intervention group, respectively), intention to stop smoking at 6 months 
follow-up had dropped again for both groups and was not significantly different from 
baseline intention to stop smoking in either the control or treatment group (t(50)=0.34, 
p=0.731 and t(47)=0.97, p=0.335, respectively).  
 
Figure 2 about here 
 
2.) Secondary outcomes 
There were no differences in terms of quit attempts; the same proportion had tried to 
stop in both the intervention (17.3%, N=14) and control group (15.2%, N=12). Logistic 
regression was conducted to predict quit attempts and included group allocation, socio-
demographic and smoking characteristics. The only predictors to emerge were past quit 
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attempts (OR 6.37; 95%CI 1.81-22.47) and cotinine level (OR 0.99; 95%CI 0.99-1.00) 
suggesting that those who had attempted to stop in the previous five years and those 
who had lower cotinine values were more likely to have attempted to quit in the following 
6 months. 
 
Overall, 5% (95%CI 2.2-9.6) of participants were abstinent at 6 months. While more 
smokers in the intervention (6.2%, N=5) than control group (3.8%, N=3) had stopped at 
follow up, this difference was not significant (Fisher’s exact test, p=0.374). Logistic 
regression including group allocation, socio-demographic and smoking characteristics 
yielded no significant baseline predictor of abstinence, although those who were less 
nicotine dependent were marginally more likely to have quit smoking (OR 0.45; 95%CI 
0.20-1.05; p=0.065). 
 
As the distribution of data yielded unstable results in logistic regression, log-linear 
models were fitted to evaluate the possibility of baseline self-efficacy moderating the 
effect of the intervention on smoking cessation. Self-efficacy moderated the impact of 
the intervention on smoking cessation as shown by a significant three-way effect of 
smoking rate at follow-up, baseline self-efficacy level and group allocation in the log-
linear model (Likelihood ratio χ2(1)=5.82, p=0.016, see Figure 3). As expected, only in 
the intervention but not the control group were high self-efficacy levels associated with a 
greater quit rate (Fisher’s exact test, p=0.022). Indeed, in the intervention group no 
participants with low-self-efficacy had quit. Amongst those with high self-efficacy levels, 
there was a borderline effect of the intervention on smoking cessation compared with the 
control group (Fisher’s exact Test, p=0.089). Interestingly, baseline self-efficacy did not 
moderate the impact of the intervention on quit attempts. 
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Figure 3 about here 
 
Sobel mediation analysis showed that post-intervention fear levels did not mediate the 
impact of the intervention on smoking cessation. Given the moderating effects of self-
efficacy, moderated mediation was also analysed. Self-efficacy did not moderate 
mediation either in the path from treatment allocation to fear levels or in the path from 
fear levels to smoking cessation. However, the analysis confirmed that self-efficacy 
levels moderated the impact of the intervention on abstinence in the mediation model 
(group by self-efficacy interaction term coefficient 0.16, p=0.02). 
 
DISCUSSION 
The purpose of this study was twofold. The primary aim was to assess changes in 
cognitive antecedents of behaviour change following an intervention that provided 
smokers with personalised biomarker feedback of their expired air CO levels. The 
secondary aim was to evaluate the efficacy of this approach to motivate smoking 
cessation and to delineate possible moderators and mediators of behaviour change as 
postulated by the extended parallel processing model (EPPM) and the emotional 
processing model (EP). 
 
A general increase in perceived threat and efficacy levels was observed in both the 
control and treatment group. This may reflect the impact of the provided leaflet, designed 
to raise threat and efficacy appraisal, as well as the provision of brief quit advice. 
However, as hypothesised, personalised quit advice incorporating CO level feedback led 
to a greater change in perceived susceptibility in treatment group participants compared 
with the generic quit advice that was provided to control group participants. Given that 
our perceived susceptibility measure asked smokers to rate their disease risk compared 
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with non-smokers, this suggests that biomarker feedback may reduce unrealistic 
optimism regarding the acquisition of smoking-related diseases. Moreover, as 
anticipated, showing smokers evidence of exposure to, and thus potential harm from, 
cigarette smoke increased their fear levels across visits but not significantly more than in 
the control group. These results are consistent with EP theory in that the presentation of 
CO levels (fear-inducing material) would have enabled access to the fear network 
(leading to increased fear levels), which could then, by presentation of incongruent 
material (quit advice and leaflet) be modulated to include new information resulting in 
changed threat perceptions (increased susceptibility). Consequently, there was also an 
increase in intention to stop smoking in the treatment group compared with the control 
group. However, this change was transient and intention levels had fallen back to 
baseline values at the six months follow-up suggesting that the stimulus used in this 
study may have been too weak to induce lasting changes in cognitions. This is 
consistent with similar transient effects on cognitive antecedents of behaviour change in 
smoking cessation trials using different biomarkers (e.g. Lerman, Gold, Audrain, Lin, 
Boyd et al., 1997; McClure, Ludman, Grothaus, Pabiniak, Richards et al., 2009). The 
findings, nonetheless, underline not only the importance of the emotive and 
preconscious level over and above a purely semantic and intellectual understanding of 
the threat of smoking but also the motivating power of emotions in order to alleviate the 
unpleasant state of fear (Easterling & Leventhal, 1989). 
 
In terms of quit attempts no group differences were observed. However, consistent with 
earlier research (Sutton, 1994; Nides, Rakos, Gonzales, Murray, Tashkin et al., 1995) 
past behaviour, i.e. attempting to quit in the last 5 years, and the amount smoked, i.e. 
cotinine levels, were predictive of future quit attempts. Seven-day point prevalence 
abstinence was five percent at the six months follow-up, which is comparable to rates 
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observed in some (Page, Walters, Schlegel, & Best, 1986; Wilson, Wakefield, Steven, 
Rohrsheim, Esterman et al., 1990) but not most other studies that have looked at the 
effect of brief smoking cessation advice (Lancaster & Stead, 2004). Although more 
people in the treatment than control group had stopped smoking, in contrast to a 
previous studies using CO feedback (Risser & Belcher, 1990; e.g. Jamrozik et al., 1984; 
Sanders et al., 1989), this difference did not reach a significant level overall. 
 
As hypothesised, self-efficacy levels moderated the impact of the intervention. Whereas 
in the treatment group there was a significant difference in smoking rates between those 
with low and high self-efficacy, there were no such differences in the control group. 
Indeed, no-one with low self-efficacy in the treatment group had stopped smoking. This 
finding would support the view that high self-efficacy may instigate behavioural (quit) and 
low self-efficacy cognitive (disengagement) solutions, therefore leading to improved 
outcome in only one of the sub-groups in the intervention. In contrast, in the control 
group, self-efficacy would not be expected to significantly moderate smoking cessation 
in the absence of sufficient threat appraisal (Witte, 1992); that is, since the intervention 
in the control condition was less intensive, perceived threat was only partly increased 
and therefore would be less likely to lead to further efficacy appraisal. However, contrary 
to expectation, fear levels did not appear to mediate the impact of the intervention on 
any behavioural outcome. This may reflect both limited power to detect mediation in the 
absence of a direct overall effect of the intervention on behavioural outcomes as well as 
the limitations of self-report in assessing fear levels. 
 
There are a number of reasons why biomarker feedback lead to short-term changes in 
cognitive antecedents of behaviour change but not to behaviour change itself. This study 
was primarily powered to detect differences in primary not secondary outcomes and 
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owing to a greater attrition than expected, power to detect more subtle differences in 
cognitive outcomes at follow-up was small. Moreover, the sample was recruited to 
participate in a laboratory study about smoking (not cessation) and were therefore not 
explicitly seeking to quit; participants were also comparatively young, both of which 
could have biased results and may explain why cessation rates in the treatment and 
control groups were at the low end compared with similar interventions using biomarker 
feedback (see Bize et al., 2009). In part, the result may also present an artefact of the 
study design. CO feedback has been shown to impact on smoking cessation when 
treatment and control conditions are not equally matched, that is when an intensive 
treatment is compared with a minimal control (Jamrozik et al., 1984; Sanders et al., 
1989). However, in the current study both treatment and control conditions were of 
similar duration to clarify the effect of expired air carbon-monoxide feedback  
 
This study has a number of limitations. The sample was not randomly selected, which 
may have introduced systematic differences in comparison with the general population. 
Yet, demographic data (with the possible exception of age) compared favourably to 
large-scale epidemiological studies. While it is assumed that the low-demand nature of 
this study minimised self-report bias on measures, this cannot be ruled out. Although 
biochemical outcome validation would have been desirable, it was not practically 
possible in this intervention. Another problem relates to the quasi-experimental design. It 
is feasible that partaking in the study itself may have led to an increase in the cognitions 
assessed as there was no control arm in which no quit advice or leaflet was provided. 
However, this is unlikely since the laboratory study did not attempt to change 
perceptions and behaviour but rather the opposite: smokers were asked to continue 
smoking as normal over the 24 hours of the study period. Lastly, in order to gauge better 
the influence of EP, it would have been preferable to include more direct measures of 
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emotional changes, such as blood pressure. As Foa and Kozak (1986) point out, people 
have an imperfect knowledge of the information contained in their fear networks, 
therefore physiological arousal would be particularly compelling evidence that their fear 
network had been activated. 
 
In conclusion, this study provides novel insights into the process of fear appeals in a 
non-clinical population that was explicitly unmotivated to quit smoking and suggests that 
the effects of offering a leaflet and brief quit advice on cognitive antecedents of 
behaviour change can be enhanced by the provision of a simple intervention designed to 
increase emotional processing. Presenting feedback of expired-air carbon-monoxide 
levels to smokers was shown to increase perceptions of susceptibility to smoking-related 
illnesses and was associated with a greater intention to stop smoking. However, findings 
suggest that these effects are short-lived and do not necessarily translate into action but 
rather are modified by perceptions of self-efficacy. This study could only provide partial 
confirmation for the causal interaction of the constructs of the EPPM and the predictions 
made by the EP theory.  
 
Future research should recruit a larger sample to overcome power issues, have an 
additional intervention arm (minimal – no leaflet or feedback) to avoid confounding and 
use more impactful biomarkers to build on the findings from this study. CO feedback 
may not be enough to instigate such behaviour change in most smokers and other more 
visually powerful biomarkers, e.g. those that display actual harm caused by smoking 
such as atherosclerotic plaques (e.g. Bovet, Perret, Cornuz, Quilindo, & Paccaud, 2002), 
may  prove generally more effective as an addendum to fear appeals and it would be 
interesting to test this in future studies. Nonetheless, this study provides some 
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preliminary evidence for the utility of a simple addendum to quit smoking advice. In 
terms of clinical practice, our results have three implications. First, while fear appeals will 
raise the issue of smoking cessation among all smokers, they may be a more effective 
tool for highly motivated and self-confident smokers and, arguably, be restricted to these 
given their potential for discouraging other smokers from quitting. Second, given that CO 
levels vary depending on the amount of cigarettes smoked, this kind of feedback may be 
particularly useful for cut-down to stop interventions as reductions in CO levels could 
over time increase efficacy perceptions of smokers and further bolster motivation to stop 
completely. Third, the effect of self-efficacy on smoking cessation and intention to stop 
highlights the need for successful smoking interventions to include techniques that can 
increase self-efficacy per se, such as proposed by Bandura (1986), in order to translate 
the momentum gained from any type of health interventions into concrete behavioural 
outcomes.  
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TABLES AND FIGURES 
Table 1: Participant characteristics# 
†
IMD: Index of multiple deprivation, BMI: Body mass index, HSI: Heaviness of smoking index (Scale 0-
6), ppm: parts per million;
 
25 cases missing; 
‡
2 cases missing 
#
There were no baseline differences between 
groups 
 
Table 2: Change in cognitive outcomes pre- to post-intervention 
Self-reported measures 
Intervention (N=81)  Control (N=79) p 
(between 
group) 
Mean Change Score (95%CI); p (within group) 
Perceived 
efficacy 
Self-efficacy   0.346  (0.101–0.590); 0.006  0.260 (-0.011–0.530); 0.059 0.638 
Response efficacy 0.253  (0.015–0.491); 0.037  0.348  (0.049–0.647); 0.023 0.620 
Perceived  
threat 
Susceptibility  0.654  (0.401–0.908); <0.001  0.272  (0.069–0.476); 0.009 0.021 
Severity 0.099 (-0.312–0.510); 0.634  0.013 (-0.136–0.162); 0.866 0.699 
Fear 
 
0.401  (0.152-0.650); 0.002  0.184 (-0.020-0.387); 0.076 0.180 
Intention to 
stop 
 
1.108  (0.793-1.420); <0.001  0.519  (0.270-0.768); <0.001 0.004 
 All smokers 
(N=160) 
 
 
Intervention 
(N=81)# 
Control 
(N=79)# 
Sociodemographic characteristics     
   Mean (SD) age 31.7 (10.7)  30.9 (10.7) 32.6 (10.8) 
   Percent (N) male 56.3    (90)  55.6    (45) 57.0    (45) 
   Mean (SD) IMD
†
 32.0 (13.1)  32.2 (13.3) 31.7 (12.9) 
   Mean (SD) BMI
†
 23.9   (4.0)  23.6   (4.1) 24.1   (3.8) 
Smoking characteristics     
   Mean (SD) cigarettes 
   per day 
13.8   (5.9)  13.4   (5.8) 14.3   (6.0) 
   Mean (SD) length of time 
   of smoking in years 
14.3 (11.1)  13.7 (11.0) 15.0 (11.3) 
   Mean (SD) HSI
†‡   2.4   (1.5)    2.3   (1.6)   2.5   (1.5) 
   Percent (N) quit attempt  
   in last 5 year 
56.3    (90)  54.3    (44) 58.2    (46) 
   Percent (N) Want to 
   quit next month 
11.3    (18)  11.1      (9) 11.4      (9) 
   Mean (SD) Baseline 
   cotinine levels in ng/ml 
224 (141)  211 (139) 237 (144) 
   Mean (SD) Post-cigarette 
   CO level in ppm
†‡ 
18.5   (7.7)  18.0   (7.5)
 
 19.1   (7.9) 
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Figure 1: Participant flow chart 
 
 
*Pre-consent data not recorded 
Assessed for eligibility=not known* 
Allocated to control group 
(N=79) 
 
Received control 
treatment (N=79) 
 
Did not receive control 
treatment (N=0) 
 
Reason: 
N/A 
Lost to follow-up (N=23) 
 
Reasons: Could not be 
contacted 
Analysed (N=79) 
 
Excluded from analysis 
(N=0) 
Allocated to intervention 
group (N=81) 
 
Received intervention 
(N=81) 
 
Did not receive 
intervention (N=0) 
 
Reason:  
N/A 
Lost to follow-up (N=28) 
 
Reasons: Could not be 
contacted 
Analysed (N=81) 
 
Excluded from analysis 
(N=0) 
Allocation 
Follow-up 
Analysis 
Session 1 consented 
(N=161) 
 
Session 2 randomised 
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Participants not 
returned for 
Session 2 (N=1) 
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Figure 2: Intention to stop smoking in the next month by group over 
time
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Figure 3: Point Prevalence Abstinence at 6 months follow up by group 
and self-efficacy level#
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